EUVIMEDOpdag EUVIMED
Crossref

Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy

Deni Hardiansyah, Nusrat Jihan Begum, Peter Kletting, Felix M Mottaghy, Gerhard Glatting

Cancer Biotherapy and Radiopharmaceuticals · 2016-08 · 31 (6) · 217-224

DOI: 10.1089/cbr.2016.2012 ↗

At a glance

Journal article in Cancer Biotherapy and Radiopharmaceuticals, 2016-08. Written by Deni Hardiansyah and 4 co-authors. Institution: 1 Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University , Mannheim, Germany. Major MEDLINE topics: Models, Biological. Cited 10 times so far (Crossref); 29 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The aim of this work was to evaluate the sensitivity of time-integrated activity coefficients (TIACs) on the erroneously chosen prior knowledge in a physiologically based pharmacokinetic (PBPK) model used for treatment planning in peptide receptor radionuclide therapy (PRRT). Parameters of the PBPK model were fitted to the biokinetic data of 15 patients after the injection of (111)In-DTPAOC. The fittings were performed using fixed parameter values taken from literature as prior knowledge (reference case, Ref). The fixed parameters were gender, physical information (e.g., body weight), dissociation rate koff, dissociation constant KD, fraction of blood flow, and spleen and liver volumes. The fittings were repeated with changed fixed parameters (Changed). The relative deviations (RDs) of TIACs calculated from Changed and Ref were analyzed for kidneys, tumor, liver, spleen, remainder, whole body, and serum. A changed koff has the largest effect on RD, the largest RD values were found for changed koff = 0.001 L/min: RDkidneys = (3 ± 3)%, RDtumor = (0.5 ± 4)%, RDliver = (6 ± 9)%, RDspleen = (5 ± 5)%, RDremainder = (2 ± 31)%, RDserum = (-4 ± 25)%, and RDwholebody = (3 ± 16)%. For other changed parameters, the maximum RDs were

Subjects

MeSH terms (MEDLINE)

Models, BiologicalFemaleHumansMaleOctreotidePentetic AcidRadiopharmaceuticalsRadiotherapy Planning, Computer-AssistedReceptors, Peptide

Author keywords

peptide-receptor radionuclide therapy (PRRT)physiologically-based pharmacokinetic (PBPK) modelingprior knowledgetime-integrated activity coefficient (TIAC)

Substances

RadiopharmaceuticalsReceptors, PeptideSDZ 215-811Pentetic AcidOctreotide

Authors and institutions

  • 1 Medical Radiation Physics/Radiation Protection, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University , Mannheim, Germany .
  • 2 Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University , Mannheim, Germany .
  • 3 Digitale Signalverarbeitung , Information Technology Faculty, Hochschule Mannheim, Mannheim, Germany .
  • 4 Department of Nuclear Medicine, University Hospital Ulm , Ulm, Germany .
  • 5 Klinik für Nuklearmedizin, University Hospital, RWTH Aachen University , Aachen, Germany .
  • 6 Department of Nuclear Medicine, Maastricht University Medical Center (MUMC+) , Maastricht, The Netherlands .

Cite

APA

Hardiansyah, D., Begum, N. J., Kletting, P., Mottaghy, F. M., & Glatting, G. (2016). Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy. Cancer Biotherapy and Radiopharmaceuticals, 31(6), 217-224. https://doi.org/10.1089/cbr.2016.2012

Vancouver

Hardiansyah D, Begum NJ, Kletting P, Mottaghy FM, Glatting G. Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy. Cancer Biotherapy and Radiopharmaceuticals. 2016;31(6):217-224. doi:10.1089/cbr.2016.2012

BibTeX
@article{Hardiansyah2016,
  author = {Hardiansyah, Deni and Begum, Nusrat Jihan and Kletting, Peter and Mottaghy, Felix M and Glatting, Gerhard},
  title = {Sensitivity Analysis of a Physiologically Based Pharmacokinetic Model Used for Treatment Planning in Peptide Receptor Radionuclide Therapy},
  journal = {Cancer Biotherapy and Radiopharmaceuticals},
  year = {2016},
  volume = {31},
  number = {6},
  pages = {217--224},
  doi = {10.1089/cbr.2016.2012}
}
Start for free →